These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 19297126)
21. [Monoclonal antibody therapy for non-Hodgkin's lymphoma]. Paul F; Rossi JF; Cartron G Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313 [TBL] [Abstract][Full Text] [Related]
22. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders. Musto P; D'Auria F Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115 [TBL] [Abstract][Full Text] [Related]
23. [Proteins in haematology]. Clarenbach RE; Mey U Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523 [TBL] [Abstract][Full Text] [Related]
24. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078 [TBL] [Abstract][Full Text] [Related]
25. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214 [TBL] [Abstract][Full Text] [Related]
26. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. King KM; Younes A Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023 [TBL] [Abstract][Full Text] [Related]
27. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715 [TBL] [Abstract][Full Text] [Related]
28. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Grillo-López AJ Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)]. Tobinai K Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346 [TBL] [Abstract][Full Text] [Related]
30. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800 [TBL] [Abstract][Full Text] [Related]
32. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Oertel SH; Anagnostopoulos I; Bechstein WO; Liehr H; Riess HB Transplantation; 2000 Feb; 69(3):430-2. PubMed ID: 10706055 [TBL] [Abstract][Full Text] [Related]
33. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Dillman RO Semin Oncol; 2003 Aug; 30(4):434-47. PubMed ID: 12939712 [TBL] [Abstract][Full Text] [Related]
34. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S; Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456 [TBL] [Abstract][Full Text] [Related]
36. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Jabr FI Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821 [TBL] [Abstract][Full Text] [Related]
37. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122 [TBL] [Abstract][Full Text] [Related]
38. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ; Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060 [TBL] [Abstract][Full Text] [Related]
39. Induction of apoptosis and effect on CD20+ using rituximab on autologous peripheral blood stem cell harvests from patients with B cell lymphomas. Borbolla-Escoboza JR; Leon MI; Collados MT; Baez E; Baltasar S; Hernández R; Rojas JC Stem Cells Dev; 2004 Apr; 13(2):193-6. PubMed ID: 15186735 [TBL] [Abstract][Full Text] [Related]
40. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Feugier P Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]